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Abstract Sentinel lymph node (SN) biopsy is part of the
staging procedure in breast cancer patients. In this study, we
compared an intraoperative tool named one-step nucleic
acid amplification (OSNA) to our routine histological
investigation. OSNA consists of a short homogenization
step followed by amplification of cytokeratin (CK) 19
mRNA directly from the lysate. To evaluate the performance
of OSNA in comparison to histology, analysis of 343 axillary
lymph nodes (ALN) from 93 breast cancer patients was
performed with both methods. Discordant samples were
subjected to other methods. If these tests supported the
OSNA results, these samples were excluded from the study.
The concordance rate was 91.8%, sensitivity 98.1%, and
specificity 90.8% before and 95.5%, 100%, and 95.6%,
respectively, after discordant case investigation. Our results
show that OSNA is an excellent method for the detection of
metastases in lymph nodes and can be applied as an
intraoperative diagnostic approach.
Keywords OSNA . Breast cancer . Intraoperative diagnosis .
CK19 . Sentinel lymph node
Introduction
The sentinel lymph node (SN) is the first lymph node to
receive lymph drainage from the tumor area and is highly
predictive for the status of the remaining axillary lymph
nodes (ALN) [1]. Since SN biopsy is a minimally invasive
technique, it spares the patient from the unpleasant side
effects as well as morbidity associated with axillary
clearance [2] and has readily evolved into the up-to-date
standard staging procedure in clinically node-negative
breast cancer patients [3–6].
Intraoperative detection of tumor deposits in SN is
conventionally achieved by frozen sections, touch imprints,
and cytological smears. In case tumor deposits are detected
in the SN, adjuvant ALN dissection (ALND) is directly
performed. Unfortunately, these techniques suffer from a
rather low sensitivity, and the degree of tumor spread into
the lymph nodes is often underestimated [7–10]. If
postoperative in-depth histological examination [11] proves
to be positive, the patient is subjected to ALND in a second
surgery. Besides additional costs and discomfort for the
patient associated with a second surgical intervention, the
investigation of permanent sections is subject to a variety of
protocols with regard to the degree of SN sectioning,
staining procedure, and antibody used [12]. In addition, the
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evaluation of tissue sections by the pathologist might be
influenced by a subjective interpretation [13]. As a
consequence, there is a need for a standardized and
reproducible method with a high predictive value which
can be applied intraoperatively.
Molecular methods based on reverse-transcriptase poly-
merase chain reaction (RT-PCR) were employed for the
detection of metastatic deposits in lymph nodes of breast
cancer patients [14–16] and indicated usefulness as a
molecular staging tool [17] and prognostic factor [18].
Despite these promising investigations, on the condition
that nucleic acids have to be isolated beforehand, these
assays are too time-consuming for routine diagnosis within
a defined time frame.
An intraoperative molecular test system for the detection
of metastases in the SN of breast cancer patients was
provided and showed a sensitivity of 87.6% and specificity
of 94.2%. Discordant results were thought to be partly due
to the fact that different tissue sections were used for this
molecular assay and histology [19].
A different commercially available, molecular method
for intraoperative diagnosis of lymph node metastases in breast
cancer patients called one-step nucleic acid amplification
(OSNA) was previously presented [20, 21]. The semiauto-
mated OSNA assay (Sysmex, Kobe, Japan) consists of a short
sample preparation step and real-time amplification of CK19
mRNA directly from the homogenate, without any RNA
purification steps. The time to perform the assay takes 30–
40 min for 3–4 LN. This quantitative molecular assessment
allows the distinction of the size of the metastasis [20]. Also,
in patients with colorectal cancer, the OSNA method with
CK19 as a marker in tandem with frozen section histology
increased intraoperative sensitivity when compared to frozen
sections alone [22].
The aim of this study was to find out whether the
performance of the OSNA assay was comparable to
extensive histologic work-up: staining with hematoxylin
and eosin (H&E) as well as a pan-cytokeratin antibody.
Accordingly, 343 ALN from 93 German breast cancer
patients were investigated with both approaches.
Material and methods
Patient samples
ALN samples, 343, from 93 breast cancer patients were
included in this study. Patient characteristics are presented
in Table 1. They were derived from complete axillary
dissection which had been performed due to a previously
positive SN or a clinically positive lymph node. The
specimens were collected at the two participating German
institutes in this study, University Clinic of Schleswig-
Holstein in Kiel, and the Albertinen Hospital in Hamburg,
Germany. The 93 patients were fully informed about the
study and had given written consent before surgery in
compliance with the regulations of the local ethical
committees of the University of Kiel and Albertinen
Hospital.
Study design
The 343 lymph node samples were longitudinally cut into
four nearly equal slices (a, b, c, d) with a special cutting
tool consisting of three blades being either 1 or 2 mm apart,
as depicted elsewhere [20]. ALN were categorized into
groups according to their size: ALN with a minor axis
smaller than 0.4 cm were excluded from the study; lymph
nodes with a minor axis between 0.4 and 0.6 cm (group 1)
were centrally cut into four slices with the 1–mm cutting
tool; ALN between 0.6 and 1.0 cm (group 2) were centrally
cut into four slices with a 2-mm cutting tool. Lymph nodes
with a minor axis larger than 1.0 cm (group 3) were either
halved or cut into several pieces, and each piece, depending
on its size, was treated in a similar fashion as described for
groups 1 and 2. Alternate slices were allocated to the
OSNA method (a&c) and to histological work-up (b&d) at
five levels. The slices used for OSNA (a&c) were shock
frozen in liquid nitrogen and stored at −80°C before the
analysis. Histological analysis was performed for slices
b&d as outlined in a different section. Concordance and
sensitivity were determined based on the comparison of
these two methods in 343 ALN samples. All histological
investigations were done without knowing the results of the



















Table 1 Clinical characteristics
of 93 breast cancer patients
204 Virchows Arch (2009) 454:203–210
negative out of the 343 lymph node samples, as determined
by five-level histology, were cut into further levels until no
remnants remained. Specificity was calculated based on the
extended investigation of these 120 samples in order to
avoid sampling errors caused by uninvestigated material.
If discordant results between the OSNA assay and five-
level histological examination occurred, the histological
work-up of these cases was also extended until no tissue
remained in the paraffin blocks. In addition, the homogenates
of these discordant cases were also analysed by Western Blot
and quantitative RT-PCR (QRT-PCR) as depicted in a
different section. Provided that these supplemental analyses
gave the same result as the OSNA assay, these samples were
excluded from the study cohort because an uneven distribu-
tion of the metastases within pieces a, b, c, and d (tissue
allocation bias) was likely to be the case.
One-step nucleic acid amplification
OSNA with CK19 mRNA as the marker was previously
described in-depth [20]. In short, the lymph node slices a&c
were homogenized together in 4 ml of homogenizing buffer
Lynorhag, pH 3.5, (Sysmex, Kobe, Japan) on ice. Twenty
microliters of this homogenate were further used for
automated amplification of CK19 mRNA via reverse
transcription loop-mediated isothermal amplification (RT-
LAMP) [23]. Real-time amplification was accomplished
with the Lynoamp Kit (Sysmex, Kobe, Japan) on the RD-
100i (Sysmex, Kobe, Japan). Four lymph nodes can be
analyzed in one run. The degree of amplification was
detected via a by-product of the reaction, pyrophosphate
[24]. The resulting change in turbidity, upon precipitation
of magnesium pyrophosphate, was in turn correlated to
CK19 mRNA copy number/μL of the original lysate via a
standard curve which was established beforehand with three
calibrators containing different CK19 mRNA copy numbers.
Since no isolation or purification of RNA was required for
OSNA, results were available after a total of 30–40 min. The
lymph node lysates were stored at −80°C until further use.
If the CK19 mRNA copy number/μL lysate was less
than 250 copies/μL, the result was regarded as (−); copy
numbers between 250 and 5,000/μL were regarded as (+),
and copy numbers larger than 5,000/μL as (++).
Histologic work-up
Lymph node slices b&d were fixed with neutral buffered
formaldehyde and embedded in the same paraffin block.
Each slice was identified by color coding.
Two initial H&E sections (representing frozen sections
of SN), one initial level, and four additional levels with a
0.1-mm skip space were cut from the 343 blocks. Each
level consisted of four 4 μm sections: one was used for
H&E staining, one for immunohistochemistry (IHC) with
the pan anticytokeratin antibody LU5 (T-1302, Dianova,
Germany), one for CK19 IHC (M0888, clone RCK 108,
DAKO, Germany), and one spare section. For the specificity
study, the paraffin blocks of 120 histologically negative
samples, as judged by five-level histological work-up, were
cut into further levels until no remnants remained. IHC was
performed according to a standard protocol. Shortly, depar-
affinised sections were cooked in a pressure cooker in Tris–
ethylenediaminetetraacetic acid–sodium citrate buffer, pH 7.8,
for 4 min. After blocking, incubation with the primary
antibody was performed for 40 min and with the secondary
antibody for 30 min. Visualization was done with diamino-
benzidine tetrahydrochloride (Vector, Burlingame, CA, USA).
Staining with the LU5 antibody was done using the NEXES
staining automat and the I-View-Kit (Ventana, Illkirch,
France).
Metastatic deposits were recorded, according to the
TNM classification of UICC 6th and AJCC 6th edition
[25, 26] as isolated tumor cells (ITC) if their largest
diameter was smaller than 0.2 mm, as micrometastases if
they were larger than 0.2 mm but not larger than 2 mm in
diameter, and as macrometastases if they were larger than
2 mm in diameter. In concordance with the TNM
designation of ITC as pN0(i+), lymph node samples were
only regarded as positive if at least one micrometastasis or
macrometastasis was found. Consequently, lymph nodes
with ITC were considered as negative in this study.
Western Blot as part of discordant case investigation
Twenty microliters of the homogenate of discordant speci-
mens were analyzed by Western Blot for CK19. The
procedure was recently described in detail [20]. In short,
the lysate was mixed with 10 μL loading buffer containing
150 mM Tris–HCl, 300 mM dithiothreitol, 6% sodium
dodecyl sulfate (SDS), 0.3% bromophenol blue, and 30%
glycerol. The solution was boiled and subjected to
electrophoresis on a 7% (w/v) polyacrylamide gel in the
presence of SDS (PAG Mini; Daiichi Pure Chemicals,
Tokyo, Japan). Proteins were transferred to an Immobilon-
FL polyvinylidene fluoride (PVDF) membrane (Millipore,
Billierica, MA, USA). After the blocking procedure, the
blot was incubated with the primary anticytokeratin 19
antibody A53-B/A2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and developed with the ECL-Advance
detection kit (GE Healthcare, Chalfont St. Giles, UK).
CK19 protein concentrations of the lysate, as expressed in
nanograms per microliter of the original lysate, were
determined on the basis of a previously performed standard
curve created with four calibrators of known CK19 protein
concentration (Biodesign, Saco, ME). The cutoff value for
CK19 protein expression of 0.13 ng/μL (mean + 3 standard
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deviations = SD) was assigned as previously presented
[20].
QRT-PCR as part of DCI
Total RNA was extracted with the RNeasy Mini Kit
(QIAGEN, Valencia, CA, USA) from 200 μL of each
discordant sample lysate. The quality of the isolated RNA
was controlled by performing QRT-PCR of the housekeeping
gene beta-actin. QRT-PCR was carried out with CK19 and
two breast cancer-specific markers, SPDEF (SAM pointed
domain containing ETS transcription factor), and FOXA1
(forkhead box A1).
QRT-PCR was performed on the ABI Prism 7700
detector in duplicates (Applied Biosystems, Foster City,
CA, USA). Two microliters of RNA was subjected to one-
step QRT-PCR with QuantiTest SYBR Green (QIAGEN,
Hilden, Germany) as described by the manufacturer. Primer
sequences for CK19, SPDEF, FOXA1, and beta-actin
amplification are listed elsewhere [20, 21].
The cutoff levels for each marker as expressed in
threshold cycles (ct) were assigned in reference to data
obtained with several histologically negative and positive
lymph nodes, respectively. The cutoff levels were as
follows: 24 for beta-actin, 31.5 for CK19, 33.8 for FOXA1,
and 31.6 for SPDEF.
Results
OSNA versus histology
In this study, 343 ALN samples from 93 breast cancer
patients were investigated by both OSNA and histological
methods (Table 2). Two hundred eleven samples were
negative with both methods, including two samples with
ITC. One hundred four samples gave positive results with
both assays. Samples, 97 out of 104, contained a macro-
metastasis, with 90 of them expressing more than 5,000
CK19 mRNA copies/μL (++) (Fig. 1) and seven between
250 and 5,000 CK19 mRNA copies/μL (+). Seven lymph
node specimens with a histologically detectable micrometa-
stasis displayed a (++) OSNA result; however, a direct
correlation between metastasis size and copy number is not
possible since different tissue slices were investigated by
each method. H&E staining and immunostaining exhibited
concordant results except in three cases which contained a
H&E positive micrometastasis or a macrometastasis of 7 or
8 mm, and only weak or no LU5 /CK19 IHC. Remarkably,
all these samples gave (++) results in OSNA.
In one sample containing a 2-mm micrometastasis and
one sample with a micrometastasis present in only one
level, negative values in the slices used for OSNA were
observed. On the other hand, 26 histology negative
samples, including one with ITC, yielded a positive result
in the OSNA assay. Eleven of these 26 samples had rather
low CK19 mRNA copy numbers/μL (250–750 copies/μL;
Table 3).
These findings, without taking any data from additional
discordant case investigation (DCI) into account, resulted in
a concordance rate of 91.8% and sensitivity of 98.1%. The
specificity rate of 91.7% was based on the investigation of
120 histologically negative samples, in which the usual five
levels plus all additional levels available were analyzed by
histology.
Discordant case investigation
RNA and proteins were extracted from the lysates of the 28
discordant cases, followed by QRT-PCR for beta-actin,
CK19, FOXA1, and SPDEF as well as Western Blotting for
CK19. If the data obtained by those additional analyses
were consistent with the results obtained by OSNA, it was
concluded that tumor deposits were either only present in
slices b or d used for histology or in slices a or c used for
OSNA. As a consequence, these samples were excluded
from the sample cohort because, in all likelihood, a tissue
allocation bias (TAB) had occurred (Table 3).
The two histology positive/OSNA negative samples
gave negative results in both QRT-PCR and Western blot
(Table 3). In 11 of the 26 histology negative/OSNA positive
samples, the outcome of additional analyses indicated the
presence of tumor deposits in the slices a or c used for
OSNA. When these 13 samples with discordant results
between histology and OSNA were not taken into account
anymore, the concordance rate changed to 95.5% (315 out
of 330) and sensitivity to 100% (104 out of 104). The
specificity accounted for 96.5% (109 out of 114) because
discordant samples 2, 8, 10, 15, 18, and 25 were part of the
specificity study.
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Interestingly, more than one OSNA positive/histology
negative sample originated from the same patient: samples
1 and 15; samples 7, 13, and 17; samples 22–24; as well as
samples 18 and 20 came from one patient, respectively,
suggesting the presence of tumor cells in the lymph nodes
of these patients.
Discussion
Recently, several studies have addressed the intraoperative
use of molecular methods to detect metastatic deposits in
SN of breast cancer patients, with varying degree of
success. The GeneSearch breast lymph node (BLN) assay
which uses CK19 in combination with mammaglobin as
targets for RT-PCR gave concordance rates of 92.3% [19,
27] with an inferior performance at detecting micrometa-
stases, as 57% sensitivity were reported. The concordance
rates of the OSNA method as determined in two studies
were 98.2% [20] and 94.8% [21]. Whereas the BLN assay
gave negative or positive results based on ct, the results of
OSNA were categorized into (++), (+), as well as (−), and
further described by a display of CK19 mRNA copy
number as a quantitative information.
In this study, the OSNA performance versus five-level
histology (H&E staining, IHC with LU5) was evaluated in
343 ALN from 93 German breast cancer patients. The
concordance rate was 91.7%, sensitivity 98.1%, and
specificity 90.8%. Since alternate slices of the LN were
used for OSNA and histology, it is self-evident that in some
events, tumor deposits might be confined to the slices
analyzed by OSNA or to the slices used for histology
(TAB). In fact, it was recently shown that most discrep-
ancies obtained from analysis of SN by histological and
molecular approaches arise from the use of alternate slices
for each method [28]. In order to clarify if some of the
discordant results obtained in this study occurred as a
consequence of this TAB, the homogenates of these lymph
node samples were subjected to DCI by RT-PCR and
Western blotting. In both of the OSNA negative/histology
Fig. 1 Histologically negative samples (a), micrometastases (b), and
macrometastases (c; top) are correlated to CK19 mRNA copy number/
μL (bottom). The rise time, which is defined as the time point when
the turbidity reached 0.1, is related to CK19 mRNA copy number via
a standard curve which was performed beforehand with three
calibrators
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positive and 11 out of 26 OSNA positive/histology negative
samples, DCI revealed equivalent results to the ones seen in
the OSNA assay. When these specimens were removed
from the sample cohort, the concordance rate was 95.5%,
sensitivity 100%, and specificity 95.6%. It cannot be fully
excluded that even a higher proportion of discordant results
were due to TAB because the homogenates were exposed to
long storage and transport conditions which might have
lowered the concentration and quality of RNA and proteins.
This is especially true for OSNA samples with copy
numbers close to the cutoff level as QRT-PCR, and Western
blot investigation is then also likely to be close to the
detection limit.
By taking the study design into consideration, it is quite
apparent that in the OSNA assay, the whole of slices a&c
was analyzed, whereas multiple 100 μm skip ribbons of the
slices used for histology were left uninvestigated, a concept
which is inherently indicative of OSNA positive/histology
negative results. At the same time, since this protocol
reflects the real situation in its best-case scenario with
regard to routine histological investigation of sentinel
nodes, the advantage of OSNA is at hand. Even more
small metastases might have been missed if the lymph
nodes had been cut in 500 μm intervals because the
German guidelines recommend two to three sections
between 100 and 500 μm [29]. Eleven out of the 26 OSNA
positive/histology negative had CK19 mRNA copy numbers/
μL below 1,000. With 250 copies/μL as the cutoff level,
these positive OSNA results very likely indicate a low tumor
burden in the lymph nodes which was probably absent in the
tissue sections used for histological investigation.
It was reported that almost all (98.2%) breast cancer
tumors express CK19 [30]. The results obtained in the
present study support this notion, since OSNA based on
CK19 mRNA expression detected all metastases which
were reported by histology, after correcting the results for
TAB. One must keep in mind that these numbers dealing
with CK19 expression in breast cancer tumors are based on
protein but not mRNA expression. In one OSNA-positive
specimen, H&E staining revealed a macrometastases (8 mm
Table 3 Discordant case investigation
No. Histology OSNA QRT-PCR Western Blot Conclusion
Copies/μL (++/+/−) Beta-actin +/− CK19 +/− FOXA1 +/− SPDEF+/− CK19 +/−
1 – 250 (+) + − − − − Discordant
2 280 (+) + + + + + Sampling bias
3 – 320 (+) + + − − − Sampling bias
4 – 320 (+) + − − − − Discordant
5 – 330 (+) + − − − − Discordant
6 – 470 (+) Could not be performed Discordant
7 – 540 (+) + − − − − Discordant
8 – 690 (+) + + − + + Sampling bias
9 – 730 (+) + − − − − Discordant
10 – 750 (+) + + + + + Sampling bias
11 – 820 (+) + − + − − Sampling bias
12 – 1,000 (+) + −a − − − discordant
13 – 1,300 (+) + − − − − Discordant
14 – 1,500 (+) + + − − − Sampling bias
15 ITC 1,800 (+) + + + + + Sampling bias
16 – 2,100 (+) + − − − − Discordant
17 – 1,900 (+) + − − − − Discordant
18 – 12,000 (++) + + + + + Sampling bias
19 – 16,000 (++) + − − − − Discordant
20 – 18,000 (++) + − − − − Discordant
21 – 20,000 (++) + − − − − Discordant
22 – 20,000 (++) + − − − − Discordant
23 – 45,000 (++) + + − − + Sampling bias
24 – 90,000 (++) + + − + + Sampling bias
25 – 360,000 (++) + + + + + Sampling bias
26 – 52,000 (++) + − − − − Discordant
27 Micrometastasis in level 4- NDa + − − − − Sampling bias
28 Micrometastasis ND + − − − − Sampling bias
a Gave some nonspecific bands upon electrophoresis
b ND not detected
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in diameter). This metastasis exhibited a very weak reaction
with LU5 and no reaction with the CK19 antibody. This
example shows that low CK19 protein expression is no
compelling evidence for low CK19 mRNA expression.
Except this one case, all H&E-positive samples were also
positive with CK19 IHC.
In summary, the OSNA assay based on CK19 mRNA
expression proved to be a reliable and standardized tool for
the intraoperative detection of lymph node metastases in
breast cancer patients. Since OSNA showed a similar
performance to in-depth histological analyses routinely
performed in SN of German breast cancer patients, its
adoption as a clinical approach could lead to a benefit for
the patients in that unnecessary second surgeries are
avoided, and diagnosis is improved.
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